How Ketamine helps treatment resistant depression
Unipolar major depressive disorder (MDD) is one of the leading causes of depression, affecting 16 million people in the United States, and over 300 million individuals across the globe that have experienced depression. Roughly one-third of the patients that suffer with MDD do not respond to currently approved and administered antidepressants or treatments, and even in those who do, these treatments typically take several weeks or even months to achieve a noticeable effect. This is also typically termed as Treatment Resistant depression due to the slow or almost next to zero effect the current depression drugs and treatments have on this disorder.
Ketamine has garnered well deserved attention from the research communities as a promising agent for treatment-resistant depression (TRD), that uses a different mechanism of treatment than currently available treatments and medication.
Ketamine blocks NMDA receptors in the neural part of the brain responsible for causing depression or mood disorders, and triggers a signal change in the AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid] receptors of brain cells. This helps treat depression causing brain cells directly at source instead of hiding and dealing with symptoms unlike most SSRI drugs administered as antidepressants.
Ketamine is known to showcase short-term effectiveness for the treatment of nonpsychotic, treatment-resistant unipolar and bipolar major depression. Within a few hours of receiving treatment, patients who benefitted from intravenous (IV) ketamine, experienced a quick onset of clinical antidepressive response lasting an average of 3 to 14 days.
Take Your First Step Forward
What Are The Benefits of Ketamine?
Ketamine has emerged as a leading treatment for patients suffering from Treatment Resistant Depression. At Pacific Ketamine Institute, we see an 85 percent response rate or higher in patients with TRD, and symptom relief as early as 2 hours following administration and lasting up to 2 weeks. The wide range of the duration of efficacy appears to be related to variability in study populations eg, age, gender, duration of depression, and comorbidities.
The most frequently administered mode of Ketamine is through intravenous or IV.
These IV infusion therapy sessions of ketamine typically last for 60 minutes, and their benefits have been realized within short periods of time.
The effect of a single dose of ketamine appears to last up to several days for individuals with unipolar TRD and for 3 to 4 days in individuals with bipolar depression. However longer lasting results have been noticed with 6 to 12 repeated sessions within the first 3-4 weeks.
Schedule Your Consultation At Pacific Ketamine Clinic Of Los Angeles Today!
It is essential to recognize depression symptoms in daily life within us or among those who surround us. If you or your loved ones suffer from treatment resistant depression, or have experienced any symptoms that can be categorized under unipolar or bipolar major depression, please call our local Los Angeles Ketamine Clinic at (424) 332-5550 to schedule a consultation. We would love to discuss your symptoms and draft a treatment plan accordingly.
Help Is Available